Literature DB >> 26770954

Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin.

Hee Kyung Kim1, Seong Mi Moon1, Ji Hoon Moon1, Jee Eun Park1, Seonggyu Byeon1, Won Seog Kim1.   

Abstract

Entities:  

Year:  2015        PMID： 26770954      PMCID： PMC4705052          DOI： 10.5045/br.2015.50.4.254

Source DB:  PubMed          Journal:  Blood Res        ISSN： 2287-979X


× No keyword cloud information.
  9 in total

1.  Brentuximab Vedotin (SGN-35).

Authors:  Jessica Katz; John E Janik; Anas Younes
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

2.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Authors:  Anas Younes; Nancy L Bartlett; John P Leonard; Dana A Kennedy; Carmel M Lynch; Eric L Sievers; Andres Forero-Torres
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

Review 3.  How I treat NK/T-cell lymphomas.

Authors:  Eric Tse; Yok-Lam Kwong
Journal:  Blood       Date:  2013-05-07       Impact factor: 22.113

Review 4.  Natural killer-cell malignancies: diagnosis and treatment.

Authors:  Y-L Kwong
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

Review 5.  CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.

Authors:  B Falini; S Pileri; G Pizzolo; H Dürkop; L Flenghi; F Stirpe; M F Martelli; H Stein
Journal:  Blood       Date:  1995-01-01       Impact factor: 22.113

6.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Authors:  Barbara Pro; Ranjana Advani; Pauline Brice; Nancy L Bartlett; Joseph D Rosenblatt; Tim Illidge; Jeffrey Matous; Radhakrishnan Ramchandren; Michelle Fanale; Joseph M Connors; Yin Yang; Eric L Sievers; Dana A Kennedy; Andrei Shustov
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

7.  Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.

Authors:  Motoko Yamaguchi; Ritsuro Suzuki; Yok-Lam Kwong; Won Seog Kim; Yuichi Hasegawa; Koji Izutsu; Junji Suzumiya; Takayuki Okamura; Shigeo Nakamura; Keisei Kawa; Kazuo Oshimi
Journal:  Cancer Sci       Date:  2008-02-19       Impact factor: 6.716

8.  Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type.

Authors:  Junshik Hong; Sanghui Park; Hae Lim Baek; Joo Hyun Jung; Il Gyu Kang; Sun Jin Sym; Jinny Park; Jeong Yeal Ahn; Eun Kyung Cho; Seon Tae Kim; Dong Bok Shin; Jae Hoon Lee
Journal:  Int J Clin Exp Pathol       Date:  2012-10-20

9.  Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

Authors:  Steven M Horwitz; Ranjana H Advani; Nancy L Bartlett; Eric D Jacobsen; Jeff P Sharman; Owen A O'Connor; Tanya Siddiqi; Dana A Kennedy; Yasuhiro Oki
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113
  9 in total
  18 in total

Review 1.  Recent Advances in the Treatment of Peripheral T-Cell Lymphoma.

Authors:  Kamel Laribi; Mustapha Alani; Catherine Truong; Alix Baugier de Materre
Journal:  Oncologist       Date:  2018-04-19

Review 2.  [Treatment of rare cutaneous T‑cell lymphoma and blastic plasmacytoid dendritic cell neoplasm].

Authors:  U Wehkamp; M Weichenthal
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

3.  The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphoma.

Authors:  Zhenchang Sun; Wenjuan Wan; Xudong Zhang; Lei Zhang; Xin Li; Ling Li; Xinhua Wang; Feifei Nan; Hui Yu; Yu Chang; Jiaqin Yan; Zhaoming Li; Fangfang Cui; Jurui Ge; Yaqin Duo XiaXu; Xia Xu; Xiaorui Fu; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-20       Impact factor: 4.322

Review 4.  How we treat NK/T-cell lymphomas.

Authors:  Eric Tse; Wei-Li Zhao; Jie Xiong; Yok-Lam Kwong
Journal:  J Hematol Oncol       Date:  2022-06-03       Impact factor: 23.168

Review 5.  Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas.

Authors:  Jason Yongsheng Chan; Soon Thye Lim
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

Review 6.  Treatment Advances in EBV Related Lymphoproliferative Diseases.

Authors:  Kebing Lv; Ting Yin; Min Yu; Zhiwei Chen; Yulan Zhou; Fei Li
Journal:  Front Oncol       Date:  2022-04-19       Impact factor: 5.738

7.  CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.

Authors:  Yanfen Feng; Huilan Rao; Yiyan Lei; Yuhua Huang; Fang Wang; Yu Zhang; Shaoyan Xi; Qiuliang Wu; Jianyong Shao
Journal:  Chin J Cancer       Date:  2017-05-10

Review 8.  The diagnosis and management of NK/T-cell lymphomas.

Authors:  Eric Tse; Yok-Lam Kwong
Journal:  J Hematol Oncol       Date:  2017-04-14       Impact factor: 17.388

9.  CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis.

Authors:  Zihang Chen; Pujun Guan; Tong Shan; Yunxia Ye; Limin Gao; Zhi Wang; Sha Zhao; Wenyan Zhang; Li Zhang; Ling Pan; Weiping Liu
Journal:  Oncotarget       Date:  2018-01-08

Review 10.  Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.

Authors:  Boyu Hu; Yasuhiro Oki
Journal:  Front Oncol       Date:  2018-04-30       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.